Bempedoic acid

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, January 23, 2024

ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares of its common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock, at the public offering price of $1.50 per share.

Key Points: 
  • ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares of its common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock, at the public offering price of $1.50 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Esperion, are approximately $97.8 million.
  • Jefferies LLC acted as sole book-running manager for the offering.
  • A registration statement relating to the offering of common stock has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on April 26, 2022.

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

Retrieved on: 
Friday, January 19, 2024

ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, before underwriting discounts and commissions.

Key Points: 
  • ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, before underwriting discounts and commissions.
  • All of the shares of common stock are being offered by Esperion.
  • In addition, Esperion granted the underwriters a 30-day option to purchase up to an additional 8,505,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering of common stock is being made only by means of a prospectus supplement and accompanying prospectus.

Esperion Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, January 18, 2024

ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock.
  • In connection with this offering, Esperion expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • All shares to be sold in the proposed offering of common stock will be sold by Esperion.
  • This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, statements related to the terms, timing and completion of the proposed public offering, the satisfaction of customary closing conditions related to the proposed public offering and the intended use of proceeds from the proposed public offering.

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Retrieved on: 
Wednesday, January 3, 2024

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

Key Points: 
  • DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.
  • The legal action pending in the United States District Court for the Southern District of New York will be dismissed.
  • Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction.
  • The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Retrieved on: 
Wednesday, January 3, 2024

ANN ARBOR, Mich. and MUNICH, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE), the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

Key Points: 
  • DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.
  • The legal action pending in the United States District Court for the Southern District of New York will be dismissed.
  • Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction.
  • The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Retrieved on: 
Wednesday, December 13, 2023

ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations. Additionally, the maximally tolerated qualifier for statin use has been removed, and the prior limitation of use stating “the effect of NEXLIZET or NEXLETOL on cardiovascular morbidity and mortality has not been determined” has also been removed.

Key Points: 
  • These applications were accepted by the FDA which issued a PDUFA, or action, date of March 31, 2024.
  • The Company’s EMA applications also remain on track, with anticipated approval in the first half of 2024.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

Retrieved on: 
Monday, November 13, 2023

ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here.

Key Points: 
  • “In the future, it can be anticipated that virtually all atherosclerosis patients will receive aggressive inflammation inhibition along with aggressive cholesterol reduction,” Ridker added.
  • In CLEAR Outcomes, patients who were randomized to bempedoic acid experienced a 21.6% reduction in hsCRP compared to placebo at 6 months.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Retrieved on: 
Saturday, November 11, 2023

Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.

Key Points: 
  • Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.
  • TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndrome and have no symptoms of heart disease.
  • TRANSFORM aims to prove that a personalized care strategy based on a Cleerly analysis is better than usual care based on traditional cardiovascular risk factors for the primary prevention of cardiovascular events.
  • “This trial provides us the opportunity to revolutionize cardiovascular event prevention and ultimately save lives from heart disease.

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

Retrieved on: 
Saturday, August 26, 2023

ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC) 2023 Congress, taking place August 25-28, 2023, in Amsterdam, Netherlands.

Key Points: 
  • “We are pleased to share additional results from our landmark CLEAR Outcomes study in late-breaker presentations at ESC 2023,” said Sheldon Koenig, President and CEO of Esperion.
  • Of the 13,970 patients included in CLEAR Outcomes, 45.6% had diabetes, 41.5% were pre-diabetic, and 12.9% had normoglycemia.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease

Retrieved on: 
Saturday, August 26, 2023

The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.

Key Points: 
  • The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.
  • “Furthermore, the data show that treatment with bempedoic acid does not impact HbA1c levels or the incidence of new-onset diabetes.
  • This is particularly important given diabetes patients’ increased risk of a CV event regardless of the presence or not of CVD.
  • These findings reinforce bempedoic acid as an effective treatment option for LDL-C lowering and CV risk reduction in Europe.